Results of a multicenter prospective observational study “Clinical significance of hyperammonemia in patients with post-Covid syndrome (LIRA - COVID)”: efficacy of L-ornithine L-aspartate

Epidemiological data suggests that approximately 10-65% of patients with mild to moderate COVID-19 have persistent symptoms already after an acute infection, which may last for six months or more. Previous clinical studies shown similar also occur in the liver. Russian scientists studied phenomenon hyperammonemia phase COVID-19, but problem elevated blood ammonia levels post - COVID syndrome has not been before. One possible option correction is L-ornithine L-aspartate (LOLA) preparation. The aim study was investigate manifestation and possibility its by using LOLA. Eighty-three (mean age 51.71 ± 12.82) post-COVID syndrome, attention memory impairment, chronic fatigue, hyperammonemia, 2-fold increase alanine transaminase (ALT) aspartate (AST) were included into multicenter, prospective observational study. L-ornithine-L-aspartate given (3 g 3 times per day orally) 4 weeks correct hyperammonemia. Patients accessed number connection test (NCT), fatigue evaluation test, measurement ALT, AST at baseline, weeks. At week level significantly decreased 81 (97.6%). Time (sec) complete NCT 49,43 15,85 vs 64.67 24.95 baseline (p<0.001). Before treatment, majority had stage 1 hepatic encephalopathy (HE) 50.6% 1-2 (intermediate) HE 30.1%, 2 10.9%, 2.4%. After LOLA distribution changed: 41% no HE, 36.1% 22.9% longer defined. mean score 46,27 10.0 64,71 19,18 ALT 47,83 38,21 units/l 95,75 68.99 40,10 35,97 78,51 90,90 respectively This showed inclusion a dose associated significant improvement objective subjective outcomes syndrome.